ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.83
0.43%
US Tech 100
17,182.80
0.63%
S&P 500
5,064.20
0.91%
US Dollar vs CAD
1.36668
0.00%
Bitcoin
59,355.47
0.40%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) News

VSTM Verastem Inc

10.36
0.00 (0.00%)
Pre Market
Last Updated: 03:09:53
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Verastem Inc VSTM NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 10.36 03:09:53
Open Price Low Price High Price Close Price Previous Close
10.36
more quote information »

Recent News

Date Time Source Heading
4/18/202415:05BWVerastem Oncology Announces Appointment of John Hayslip,..
4/04/202406:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
3/18/202406:00BWGlobal Patient Survey Results Reveal Significant Negative..
3/14/202415:05BWVerastem Oncology Reports Fourth Quarter and Full Year 2023..
3/11/202416:07EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
3/11/202406:30BWVerastem Oncology Announces Multiple Oral Presentations at..
3/05/202416:27BWVerastem Oncology Receives Orphan Drug Designation from FDA..
3/05/202415:30BWVerastem Oncology Announces Preclinical Presentations for..
2/08/202415:22EDGAR2Form SC TO-I - Tender offer statement by Issuer
2/02/202408:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
1/29/202415:01EDGAR2Form 8-K - Current report
1/29/202406:00BWVerastem Oncology Outlines Key 2024 Strategic Priorities and..
1/19/202406:54EDGAR2Form 8-K - Current report
1/18/202415:00BWVerastem Oncology Granted Fast Track Designation for..
1/11/202406:00BWVerastem Oncology to Participate in the B. Riley Securities..
1/09/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/08/202415:02EDGAR2Form 8-K - Current report
1/05/202406:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
12/28/202315:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/21/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/20/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/20/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/19/202315:01EDGAR2Form DEF 14A - Other definitive proxy statements
12/18/202306:00BWVerastem Oncology Selects Oral KRAS G12D Inhibitor..
12/13/202306:00BWVerastem Oncology Announces Initiation of a Confirmatory..
12/08/202315:10EDGAR2Form PRE 14A - Other preliminary proxy statements
11/20/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
11/13/202306:00BWNew Healthcare Professional Component of Let’s Talk About..
11/08/202316:01EDGAR2Form S-3 - Registration statement under Securities Act of..
11/08/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/202315:12BWVerastem Oncology Reports Third Quarter 2023 Financial..
11/07/202306:00BWFirst-Of-Its-Kind, Multi-National Patient Impact Survey..
11/06/202306:00BWVerastem Oncology Announces Efficacy and Safety Data of..
10/27/202315:41EDGAR2Form 8-K - Current report
10/26/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/26/202315:05BWVerastem Oncology Strengthens Executive Leadership Team with..
10/18/202315:50BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
10/14/202311:30BWVerastem Oncology Announces Initial Results of RAMP 203..
10/10/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/06/202306:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
9/28/202313:27EDGAR2Form 8-K - Current report
9/28/202313:15BWVerastem Presents Avutometinib and Defactinib Combination..
9/25/202315:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/20/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/20/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/12/202315:08EDGAR2Form 8-K - Current report
9/05/202306:00BWVerastem Oncology to Participate in Upcoming Investor..
8/28/202306:00BWVerastem Oncology Enters Discovery and Development..
8/08/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/202315:05BWVerastem Oncology Reports Second Quarter 2023 Financial..

Your Recent History

NASDAQ
VSTM
Verastem
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved